Literature DB >> 3566714

Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators.

G J Kontoghiorghes, S Chambers, A V Hoffbrand.   

Abstract

The heteroaromatic chelators 1,2-dimethyl-3-hydroxypyrid-4-one, maltol, mimosine and 2,4-dihydroxypyridine-N-oxide, have been shown to mobilize iron from human spleen haemosiderin, ferritin and also from iron(III) precipitates, all containing equal amounts of iron, at physiological pH. In the case of almost every chelator, the least-solubilized polynuclear iron form was ferritin, whereas haemosiderin was more soluble and the iron(III) precipitate the most soluble of all. Most of the chelators were more efficient than desferrioxamine at releasing iron from ferritin, but less efficient in the removal of iron from the other two polynuclear iron forms. It is suggested that the chelator differences in iron mobilization may be related to variations in the chelator molecular structure, the protein structure, iron forms and in the mechanism of iron release.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566714      PMCID: PMC1147528          DOI: 10.1042/bj2410087

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Mobilisation of iron from ferritin fractions of defined iron content by biological reductants.

Authors:  J Dognin; R R Crichton
Journal:  FEBS Lett       Date:  1975-06-15       Impact factor: 4.124

Review 2.  The iron-loaded cell--the cytopathology of iron storage. A review.

Authors:  G W Richter
Journal:  Am J Pathol       Date:  1978-05       Impact factor: 4.307

3.  Ferritin in synovial cells in patients with rheumatoid arthritis.

Authors:  K D Muirden
Journal:  Ann Rheum Dis       Date:  1966-09       Impact factor: 19.103

4.  On the structure of hemosiderin and its relationship to ferritin.

Authors:  F A Fischbach; D W Gregory; P M Harrison; T G Hoy; J M Williams
Journal:  J Ultrastruct Res       Date:  1971-12

5.  [Syntheses of N-substituted-3-glucosyloxy-2-methyl-4-pyridones and their aglycones].

Authors:  M Yasue; N Kawamura; J Sakakibara
Journal:  Yakugaku Zasshi       Date:  1970-10       Impact factor: 0.302

6.  Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis.

Authors:  S C FINCH; C A FINCH
Journal:  Medicine (Baltimore)       Date:  1955-12       Impact factor: 1.889

7.  [Formation of pyridone derivates from maltose and lactose. XII. Investigations on the Maillard-reaction (authors transl)].

Authors:  T Severine; A Loidl
Journal:  Z Lebensm Unters Forsch       Date:  1976

8.  Iron mobilization from ferritin by chelating agents.

Authors:  R R Crichton; F Roman; F Roland
Journal:  J Inorg Biochem       Date:  1980-12       Impact factor: 4.155

9.  Uptake and release of ferritin iron. Surface effects and exchange within the crystalline core.

Authors:  T G Hoy; P M Harrison; M Shabbir
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

10.  Ferritin iron uptake and release. Structure-function relationships.

Authors:  P M Harrison; T G Hoy; I G Macara; R J Hoare
Journal:  Biochem J       Date:  1974-11       Impact factor: 3.857

View more
  17 in total

1.  Low molecular weight iron and the oxygen paradox in isolated rat hearts.

Authors:  A Voogd; W Sluiter; H G van Eijk; J F Koster
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Mimosine-induced apoptosis in C6 glioma cells requires the release of mitochondria-derived reactive oxygen species and p38, JNK activation.

Authors:  Shanlou Qiao; Keiko Murakami; Qinghong Zhao; Baoling Wang; Hisao Seo; Hitoshi Yamashita; Xiaotao Li; Takashi Iwamoto; Masatoshi Ichihara; Masataka Yoshino
Journal:  Neurochem Res       Date:  2011-10-11       Impact factor: 3.996

3.  Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains.

Authors:  Ajay Singh; Liuting Qing; Qingzhong Kong; Neena Singh
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

Review 4.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

5.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

6.  Iron release from ferritin and its sensitivity to superoxide ions differs among vertebrates.

Authors:  L R Harris; M H Cake; D J Macey
Journal:  Biochem J       Date:  1994-07-15       Impact factor: 3.857

7.  Iron release from haemosiderin and ferritin by therapeutic and physiological chelators.

Authors:  M J O'Connell; R J Ward; H Baum; T J Peters
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

Review 8.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 9.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Iron release from haemosiderin and production of iron-catalysed hydroxyl radicals in vitro.

Authors:  M Ozaki; T Kawabata; M Awai
Journal:  Biochem J       Date:  1988-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.